☆ 4.6 Meeting Abstract

ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy

JOURNAL OF THORACIC ONCOLOGY (2019)

Get Full Text
Add to Collection

Journal

JOURNAL OF THORACIC ONCOLOGY
Volume 14, Issue 10, Pages S647-S647

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtho.2019.08.1366

Keywords

NSCLC; resistance; Osimertinib

Categories

Oncology Respiratory System

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.